Evidence map›Paper›PMID 21192942›Full record

ArticleJournal of immunological methods2011

A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples.

Margaret E Ackerman, Brian Moldt, Richard T Wyatt, Anne-Sophie Dugast, Elizabeth McAndrew, Stephen Tsoukas, Stephanie Jost, Christoph T Berger, Gaia Sciaranghella, Qingquan Liu and 3 more

Erratum issuedAbstract read
In one paragraph

Article in Journal of immunological methods, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 363 papers.

0numbers the graph read from it
0cells of the map it votes in
363citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

363 citing papers in PubMed, 467 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

303 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Margaret E AckermanRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, MA, United States. meackerman@partners.org
Brian Moldt
Richard T Wyatt
Anne-Sophie Dugast
Elizabeth McAndrew
Stephen Tsoukas
Stephanie Jost
Christoph T Berger
Gaia Sciaranghella
Qingquan Liu
Darrell J Irvine
Dennis R Burton
Galit Alter
Ragon Institute of MGH, MIT and Harvard · USScripps Research Institute · USInternational AIDS Vaccine Initiative · USMassachusetts Institute of Technology · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Antibody Effector Function in Protection Against HIV-1R37AI055332 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2009 to 2018
$9.7M
Demystifying the antiviral activity of the IgG3+ antibody responseR37AI080289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2015 to 2022
$5.8M
Demystifying the antiviral activity of the IgG3+ antibody responseR01AI080289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI JUELG, BORIS DOMINIK · 2009 to 2024
$4.1M
ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1R01AI055332 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2003 to 2007
$3.8M
NIAID NIH HHS AI055332NIAID NIH HHS AI080289NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI080289
6 · The paper itself

Abstract

Phagocytosis can be induced via the engagement of Fcγ receptors by antibody-opsonized material. Furthermore, the efficiency of antibody-induced effector functions has been shown to be dramatically modulated by changes in antibody glycosylation. Because infection can modulate antibody glycans, which in turn modulate antibody functions, assays capable of determining the induction of effector functions rather than neutralization or titer provide a valuable opportunity to more fully characterize the quality of the adaptive immune response. Here we describe a robust and high-throughput flow cytometric assay to define the phagocytic activity of antigen-specific antibodies from clinical samples. This assay employs a monocytic cell line that expresses numerous Fc receptors: including inhibitory and activating, and high and low affinity receptors--allowing complex phenotypes to be studied. We demonstrate the adaptability of this high-throughput, flow-based assay to measure antigen-specific antibody-mediated phagocytosis against an array of viruses, including influenza, HIV, and dengue. The phagocytosis assay format further allows for simultaneous analysis of cytokine release, as well as determination of the role of specific Fcγ-receptor subtypes, making it a highly useful system for parsing differences in the ability of clinical and vaccine induced antibody samples to recruit this critical effector function.

Indexed as

PhagocytosisAntibodiesAntibodies, BlockingAntibody SpecificityCell LineCytokinesFlow CytometryGlycosylationHIV InfectionsHumansImmunity, InnateImmunoassayImmunoglobulin GInfluenza, HumanIn Vitro TechniquesMicroscopy, ConfocalAntibodiesAntibodies, BlockingCytokinesImmunoglobulin GReceptors, IgGRecombinant ProteinsVaccines

Identifiers

PMID21192942
PMCPMC3050993
OpenAlexW2081305632

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.